‘GIMS Pro’

As GIMS foundation we have a focus on the improvement of Medication Safety in LMIC’s.  IT is one of the ways to help pharmaceutical professionals to be able to perform these tasks towards their community.  That is why we are in the process of creating ‘GIMS Pro’.

Goal:

Create (locally customized and serviced) open source IT products (software and a national product database) focussed upon pharmaceutical professionals which will be able to help to enhance Medication Safety for the general public in LMIC’s.

These IT products require nationally organized supporting entities for education, technical support, maintenance and further national development.

Ideally these entities are, or will be, incorporated in a national Professional Pharmaceutical Society, or likewise, so the professionals themselves can direct the desired functional IT- and organisational goals/destination, and shall have no commercial goals.

Path:

-The specific national situation (technical, judicial, economical, safety and professional attitude) is sufficiently adequate to start the process.

-GIMS foundation operates as the party which supplies the licence (free of charge) for the standardized IT-products.

-GIMS foundation delivers the corresponding consultancy in the process of realising the nationally desired versions and entities.

-The national entities are, for their territory, the owner of the nationally developed ‘GIMS Pro’-versions.

-GIMS foundation functions after national implementation as a GIMS-family in which users are connected and further developments are guided.

Technical:

-Internet based,

-open source software,

-both a product database and corresponding software is needed,

-product data base derived from the Dutch ‘G-standaard’ and adepted to local situation,

-ideally a patient file database is possible,

-the software should be very flexible in the desired/operational functionalities,

Technical:

-Internet based,

-open source software,

-both a product database and corresponding software is needed,

-product data base derived from the Dutch ‘G-standaard’ and adepted to local situation,

-ideally a patient file database is possible,

-the software should be very flexible in the desired/operational functionalities,

-functionalities can be:

*Dosage control (age and sex dependent)

*Checks on Interactions between co-used medicines

*Checks on Contra-indications:

#Diabetes

#High blood pressure

#Asthma

#HIV, TB, Malaria

#Pregnancy

#Intolerances

#Kidney function

*(pro-)active searches in case of the availability of adequate patient files

 

What say others about GIMS?

“I would like to recommend the importance of the GIMS-Foundation initiative. In general there is a focus on accessability, affordability and quality of the medication in low and middle income countries, but the actual consumption of medication poses new and other questions. Questions wether the right person uses the right medicine, in the right dose, for the right amount of time, in compliance with the advises. The use of medication is always a balance between the expected benefits and the potential side-effects. Lack of balance threatens the patient. Disregarding the medication safety undermines the benefits, is a potential hazard, and is a waste of money. Monitoring medication safety is a key element in the work of health care professionals. The World Health Organization stimulates countries all over the world to establish national bodies for rational use of medicine in particular to find a balance between quality, safety and costs of the actual use of medication. The GIMS Foundation contributes to this balance by stimulating initiatives to guarantee the medication safety and is a partner for local, regional and national organizations. The Dutch Institute for Rational Use of Medicine (IVM) has been very successful in the last 20 years to create the best benefit/risk ratio in the use of medicines in the Netherlands, leading to for example an optimal use of antibiotics and therefore the lowest level of antibiotic resistance in the world. We achieved this in close cooperation with general practitionars, specialists and pharmacists. We thus support the work of the GIMS Foundation and we are willing to cooperate in every possible way.”

Drs. Ruud Coolen van Brakel, director IVM, Dutch Institute for Rational Use of Medicine

Medicine related hospital admissions

In the beginning of 2017 a follow up report (of the HARM study and HARM Wrestling report, see GIMS library) was released which made clear that:

For patients over 65 years:

Investigation period was 2008-2013,

10% of the hospitalisations were medicine related,

50% of these were potentially avoidable!

for the Dutch situation that comes down to about 50.000 potentially avoidable hospitalisations per year!

For report:

eindrapport-vervolgonderzoek-medicatieveiligheid (1)

Electronic prescription is a must have

In a just relased Dutch Health Inspectorate Investigational  Report titled,  in translation,  ‘Safe prescription must (be) better’ it is stated as an absolute demand that, in order to minimize errors etc, the prescription must be electronical.

veilig-voorschrijven-moet-beter 2017

LMIC’s should also be able to implement some form of electronic prescribing (and dispensing) system in order to help prevent health care risks, from the unsafe prescription/dispensing and use of medicines, for their populations. At the GIMS foundation we are currently working on such a (broadly applicable) IT-tool.

The GIMS model 1.0

The ‘GIMS model for screening and rating Medication Safety in a country 1.0’ is out!

This analytical tool with a new and comprehensive approach, regarding all the actors and factors influencing Medication Safety in a country,  is of use for scientific and pharmaceutical policy research as it identifies the actual status and brings focus on possible improvements.

GIMS foundation invites fellow researchers to comment.

GIMS model version 1.0

 

Chicago area; 52% of dangerous drug interactions were missed

The Chicago Tribune published on the 15th December 2016 a great piece of investigative journalism which took 2 years to perform.

The result is vastly shocking; out of the 255 selected pharmacies (big chains aswell as independent pharmacies) a staggering 52% did NOT mention the potential serious interactions to the patients.

For the full article use the link underneath.

http://www.chicagotribune.com/news/watchdog/druginteractions/ct-drug-interactions-pharmacy-met-20161214-story.html

At GIMS foundation we argue; if even in a High Income country like the USA such a bad result is obtained, what would the situation be in Low- & Middle Income countries….

That is why in these countries the improvements on the ‘Acces to medication-theme’ should be accompagnied by Medication Safety measures!

 

Pay only for results

With the arrival of new, mainly anti-cancer, drugs which are targeted at small populations and which are very/extremely high priced, international discussions are intensifying how to deal with the budget consequences. Especially when such a specific medicine does not reach 100% efficacy.

One of the lines of thinking, proposed by the pharma industry, consists of making definitive payment dependend upon achieved individual therapeutic results. So if there is no result, there will be no payment.

At GIMS we welcome this concept, but at the same time argue that this concept should ALSO be applied to other groups of less expensive medicines. Then industry would also be more interested in having a positive influence on the results of other chain partners.

In the end, medicines are ‘just a mean’ in reaching a desired health result, or therapeutic outcome, for which society is willing/able to pay.

EFPIA and Medication Safety

EFPIA (being the European Federation of Pharmaceutical Industries and Associations) states it very clearly in their Annual Report 2015:

‘Our Vision: We support a vision of outcomes driven, sustainable healthcare systems ……..and ensure the highest security of the medicines supply chain.’

‘Our Commitment: Improving patient outcomes……and improving patient safety…..By working in partnership with all health care stakeholders, we seek to develop practical solutions to make these goals a reality.’ 

At GIMS we warmly welcome these explicit words, commitments and co-responsibilities.